JP2022511881A - 操作されたフラジェリン由来の組成物と用途 - Google Patents

操作されたフラジェリン由来の組成物と用途 Download PDF

Info

Publication number
JP2022511881A
JP2022511881A JP2021532369A JP2021532369A JP2022511881A JP 2022511881 A JP2022511881 A JP 2022511881A JP 2021532369 A JP2021532369 A JP 2021532369A JP 2021532369 A JP2021532369 A JP 2021532369A JP 2022511881 A JP2022511881 A JP 2022511881A
Authority
JP
Japan
Prior art keywords
amino acid
flagellin
hydrophilic
residue
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021532369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511881A5 (cg-RX-API-DMAC7.html
Inventor
メット,ヴァディム
グドコフ,アンドレイ
Original Assignee
ゲノム プロテクション,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゲノム プロテクション,インコーポレイテッド filed Critical ゲノム プロテクション,インコーポレイテッド
Publication of JP2022511881A publication Critical patent/JP2022511881A/ja
Publication of JP2022511881A5 publication Critical patent/JP2022511881A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021532369A 2018-12-07 2019-12-06 操作されたフラジェリン由来の組成物と用途 Pending JP2022511881A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776507P 2018-12-07 2018-12-07
US62/776,507 2018-12-07
PCT/US2019/064954 WO2020118192A1 (en) 2018-12-07 2019-12-06 Engineered flagellin-derived compositions and uses

Publications (2)

Publication Number Publication Date
JP2022511881A true JP2022511881A (ja) 2022-02-01
JP2022511881A5 JP2022511881A5 (cg-RX-API-DMAC7.html) 2022-12-14

Family

ID=70974397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021532369A Pending JP2022511881A (ja) 2018-12-07 2019-12-06 操作されたフラジェリン由来の組成物と用途

Country Status (10)

Country Link
US (1) US20220024991A1 (cg-RX-API-DMAC7.html)
EP (1) EP3890769A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022511881A (cg-RX-API-DMAC7.html)
KR (1) KR20210111770A (cg-RX-API-DMAC7.html)
CN (1) CN113382742A (cg-RX-API-DMAC7.html)
AU (1) AU2019392903A1 (cg-RX-API-DMAC7.html)
CA (1) CA3122067A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191610A1 (cg-RX-API-DMAC7.html)
IL (1) IL283757A (cg-RX-API-DMAC7.html)
WO (1) WO2020118192A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102720967B1 (ko) * 2020-06-04 2024-10-23 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물
CN119522108A (zh) * 2022-06-01 2025-02-25 弗莱格生物公司 Rna佐剂、其方法和用途
KR102896818B1 (ko) * 2022-10-19 2025-12-08 전남대학교 산학협력단 Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용
KR20240081501A (ko) * 2022-11-14 2024-06-10 전남대학교산학협력단 암의 치료용 면역증강 살모넬라 균주 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524890A (ja) * 2011-05-21 2014-09-25 マクロジェニクス,インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
JP2016512251A (ja) * 2013-03-14 2016-04-25 リサーチ コーポレーション テクノロジーズ インコーポレイテッド サルシン及び他の関連する真菌リボトキシンに由来するリボトキシン分子
JP2017523184A (ja) * 2014-07-30 2017-08-17 クリーブランド バイオラブズ,インコーポレイテッド フラジェリン組成物および使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121734B1 (en) * 2007-02-09 2013-05-08 Industry Foundation of Chonam National University Modified flagellin improved toll-like receptor 5 stimulating activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524890A (ja) * 2011-05-21 2014-09-25 マクロジェニクス,インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
JP2016512251A (ja) * 2013-03-14 2016-04-25 リサーチ コーポレーション テクノロジーズ インコーポレイテッド サルシン及び他の関連する真菌リボトキシンに由来するリボトキシン分子
JP2017523184A (ja) * 2014-07-30 2017-08-17 クリーブランド バイオラブズ,インコーポレイテッド フラジェリン組成物および使用

Also Published As

Publication number Publication date
CA3122067A1 (en) 2020-06-11
US20220024991A1 (en) 2022-01-27
IL283757A (en) 2021-07-29
EA202191610A1 (ru) 2021-10-25
CN113382742A (zh) 2021-09-10
AU2019392903A1 (en) 2021-06-24
EP3890769A4 (en) 2022-11-23
EP3890769A1 (en) 2021-10-13
KR20210111770A (ko) 2021-09-13
WO2020118192A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
US11034733B2 (en) Flagellin compositions and uses
KR20220068240A (ko) 암 치료를 위한 암 요법과 사이토카인 조절 요법의 조합
JP7402691B2 (ja) 抗cd25抗体薬物複合体による併用療法
US10196435B2 (en) OX40L fusion protein for the immunotherapy of tumors of veterinary animals
JP2021502808A (ja) がんの処置におけるcar−t細胞またはcar−nk細胞を用いるlilrb4のターゲティング法
US20220024991A1 (en) Engineered flagellin-derived compositions and uses
TW202233249A (zh) 藉由投與抗b7-h3抗體-藥物結合物之間皮瘤之治療
JP2020517629A5 (cg-RX-API-DMAC7.html)
JP2022522775A (ja) Lilrb4結合抗体およびその使用方法
JP7740994B2 (ja) 抗cd19抗体薬物複合体とpi3k阻害剤又は二次薬剤を含む併用治療
RS53327B (sr) Monoklonsko antitelo na cd44, za korišćenje u lečenju karcinoma skvamoznih ćelija glave i vrata
WO2016014899A1 (en) Flagellin derivatives and uses
US20250145715A1 (en) B7-h3 targeting fusion proteins and methods of use thereof
JP7590083B2 (ja) 併用療法
JP2025179057A (ja) 併用療法のための患者の選択
EP4031655A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
US10912791B2 (en) Compositions comprising antisense-encoded erythropoietin receptor and use thereof
HK1237803A1 (en) Flagellin compositions and uses
HK1237803B (en) Flagellin compositions and uses
Wagner Investigation of a Novel Small Molecule TRAIL Inducer, ONC201: Pre-clinical Anti-cancer Efficacy, Anti-metastasis Effects, Tumor Immunity; and the Structure-activity Relationships (SAR) and Mechanism of Action of Potential Analogues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240730